Federal Register Notice: FDA has determined the regulatory review period for AstraZeneca’s Vandetanib is 4,009 days for extending a patent which claims the human drug product. Vandetanib is indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. To view this notice, click here.
